DDOX expands the repertoire of tetracyclines for Parkinson’s disease by preventing the cellular uptake and intracellular impact of α-synuclein preformed fibrils
9.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-10-30 03:37
摘要：
DDOX, a non-antibiotic derivative of doxycycline, exhibits promising neuroprotective effects against Parkinson's disease by inhibiting α-synuclein aggregation and reducing lysosomal stress. The study reveals DDOX's multifaceted mechanisms, including interference with α-synuclein fibril uptake, suggesting its potential as a therapeutic candidate for further clinical exploration. These findings underscore the need for innovative treatments targeting the underlying pathophysiology of neurodegenerative diseases.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
DDOX inhibits α-Syn aggregation and seeding in vitro.
DDOX mitigated lysosomal stress induced by α-Syn PFF.
DDOX shows potential for further investigation in preclinical and clinical settings.
真实性检查
否
AI评分总结
DDOX, a non-antibiotic derivative of doxycycline, exhibits promising neuroprotective effects against Parkinson's disease by inhibiting α-synuclein aggregation and reducing lysosomal stress. The study reveals DDOX's multifaceted mechanisms, including interference with α-synuclein fibril uptake, suggesting its potential as a therapeutic candidate for further clinical exploration. These findings underscore the need for innovative treatments targeting the underlying pathophysiology of neurodegenerative diseases.